|
|
|
|
Pharmaceutical Product List T-Z - Novartis.com
Search Novartis.com - Go Novartis.com Home Products Pharmaceutical Best Sellers Pharmaceuticals CIBA Vision Animal Health Over the Counter Infant and Baby Medical Nutrition Diseases & Conditions About Novartis Investor Relations Media Relations Careers Corporate Citizenship Business Development Our Mission Our Businesses Leadership & Governance Research & Development Foundations...
|
|
|
Genentech: Investor Relations - Financials - 2003 Third Quarter Report
We achieved several important milestones in the third quarter that move us closer to our 5X5 goal of five product approvals by the end of 2005: the launch of Xolair® (Omalizumab), the U.S.
The launch of Xolair into the allergic asthma market is going well for Genentech and Novartis.
As of mid-September, over 1,500 allergists and pulmonologists are...
|
|
|
Genentech: Investor Relations - Financials - 2004 Second Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year Financial Summary Literature...
|
|
|
Genentech: About Us - Corporate Overview - Corporate Growth Strategy
Home Contact Us Site Index Search [ About Us -- Corporate Overview -- Corporate Growth Strategy -- 5X5 Goals ] Corporate Overview Home History Awards & Recognition Corporate Growth Strategy 5x5 Goals--- Horizon 2010 Compliance Programs 5X5 Goals Our 5X5 goals began in 1999 and continue in place through 2005.
5 new products/indications approved With the nine approvals of Nutropin...
|
|
|
Genentech: Investor Relations - Financials - 2004 First Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2004 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Investor Relations - Financials - 2001 Second Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Investor Relations - Financials - 2001 Third Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Investors - FAQs
FDA Approval *Protropin®, growth hormone Growth hormone deficiency in children 10/17/1985 - Nutropin®, growth hormone Growth failure associated with chronic renal insufficiency 11/17/1993 - Growth hormone deficiency in children 03/08/1994 - Short stature associated with Turner Syndrome 12/30/1996 - Growth hormone deficiency in adults 12/15/1997 - Long-term treatment of...
|
|
|
Genentech: Investor Relations - Financials - 2003 Second Quarter Report
Then, in June, Xolair® (Omalizumab) was granted approval by the U.S.
were very pleased with the FDA approval of Xolair on June 20, 2003 for the treatment of adults and adolescents (12 years of age and above) with moderate-to-severe persistent asthma who are inadequately controlled with inhaled corticosteroids.
Xolair is the first approved therapy to...
|
|
|
Genentech: Investor Relations - Financials - 2002 Second Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2002 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Investor Relations - Financials - 2002 Third Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2002 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Investor Relations - Financials - 2003 First Quarter Report
announced in March that we had received notification that the Food and Drug Administration's (FDA) Pulmonary Allergy Drugs Advisory Committee meeting for Xolair™ (Omalizumab) will take place on May 15, 2003.
As part of our future planning for Xolair, we and our alliance companies are continuing to discuss next steps for indications in IgE-mediated diseases...
|
|
|
Oncology, Immunological Disease, Vascular Medicine and Biotherapeutics information
Immunology RAPTIVA® (efalizumab) Anti-CD11a antibody For chronic moderate-to-severe plaque psoriasis in adults age 18 or older Xolair® (Omalizumab) for Subcutaneous Use Anti-IgE antibody For moderate-to-severe persistent asthma in adults and adolescents Vascular Medicine Activase® (Alteplase) A tissue-plasminogen activator For acute myocardial infarction,...
|
|
|
Allergic Rhinitis - Quest Diagnostics Patient Health Library
Allergic Rhinitis Medications Many medications are available for treating allergic rhinitis.
It may take a combination of medications to relieve all of your symptoms.
Decongestants help clear the nose but do not help much with sneezing and itching.
Leukotriene modifiers may relieve nasal congestion, itching and sneezing, and a runny nose.
Omalizumab (Xolair)...
|
|
|
Allergic Rhinitis - Quest Diagnostics Patient Health Library
Allergic Rhinitis Treatment Overview Treatment for allergic rhinitis consists of avoiding the specific allergens causing your symptoms, using medications, and, in severe cases, getting allergy shots ( immunotherapy ).
Initial treatment Initial treatment of allergic rhinitis includes taking steps to reduce or eliminate exposure to the allergens causing your symptoms and using...
|
|
|
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf
Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA (1) Pro forma basis: This report reflects the adoption of new IFRS accounting standards that became effective on January 1, 2005, and other presentational changes.
In the US, third- quarter sales advanced 11% to USD 2.1 billion as strong performances...
duplicates:
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf page 9
duplicates:
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA 1/ 7 Investor Relations Release Novartis presents positive Phase III data on key compounds and highlights strong late- stage development pipeline · New first- in- class compounds LAF237 (diabetes) and SPP100 (hypertension) set for submission in...
duplicates:
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf page 6
duplicates:
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
|
|
|
Results -- View
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
Results -- View
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
BIOPHARMA FDA Approvals
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
LeadDiscovery - Emerging Drug Discovery Targets October 21 2003
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
IDEC-152 as a candidate treatment of asthma
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
Asthma Improvements to Combination Inhalers Will Satisfy a Growing Patient Base
Reasons to Purchase Learn what drugs in late-development will have the greatest impact on future prescribing trends, and in particular the outlook for disease modifiers- Investigate if Altana’s/Pfizer’s new PDE-4 inhibitor Daxas (roflumilast) will impact sales of Singulair (montelukast)- Determine initial patient and physician reaction to Xolair (omalizumab) and...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
|
